Cardiometabolic Risk in First Degree Relatives of Women With Polycystic Ovary Syndrome (PCOS).

IF 2.4 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Clinical Endocrinology Pub Date : 2025-06-24 DOI:10.1111/cen.15294

Su Jen Chua, Xinyi Wu, Tahani Al Kindi, Bulent O Yildiz, Aya Mousa, Loyal Pattuwage, Helena Teede, Anju E Joham, Chau Thien Tay

{"title":"Cardiometabolic Risk in First Degree Relatives of Women With Polycystic Ovary Syndrome (PCOS).","authors":"Su Jen Chua, Xinyi Wu, Tahani Al Kindi, Bulent O Yildiz, Aya Mousa, Loyal Pattuwage, Helena Teede, Anju E Joham, Chau Thien Tay","doi":"10.1111/cen.15294","DOIUrl":null,"url":null,"abstract":"Objective: Polycystic ovary syndrome (PCOS) is a common multisystem disorder with reproductive, cardiometabolic and psychological implications. Genetic factors play a role in the pathogenesis of PCOS. We sought to investigate the cardiometabolic health of first degree relatives (FDR) of women with PCOS.Design: Systematic review and meta-analysis.Methods: Medline, Embase, PsycInfo, allEBM (Ovid), clinicaltrials.gov and WHO ICTRP were searched from inception until 1st November 2023. Randomised controlled trials, observational studies, evidence-based guidelines, systematic reviews and health technology assessments reporting on cardiometabolic health of FDRs of women with PCOS compared to participants without a family history of PCOS (controls) were included. Primary outcomes of interest were cardiovascular disease and cardiometabolic risk factors. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were adhered to for the systematic review and meta-analysis.Results: The search strategy identified 20,639 publications of which 68 publications representing 34 unique studies were included. FDRs of women with PCOS had higher rates of metabolic syndrome (OR: 2.50; 95% CI: 1.40-4.45, I2 = 65%; six studies; 2059 participants; p = 0.002), hypertension (OR: 2.05; 95% CI: 1.08-3.92, I2 = 0%; three studies; 302 participants; p = 0.03) and diabetes (OR: 2.46; 95% CI: 1.31-4.62, I2 = 9%; five studies; 778 participants; p = 0.005) compared with controls. Additionally, measures of glucose control and lipid profile were worse in FDRs of women with PCOS compared with controls. Most studies were judged as moderate risk of bias. No published data on CVD were identified.Conclusions: FDRs of women with PCOS are at increased risk of cardiometabolic disorders.","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cen.15294","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Polycystic ovary syndrome (PCOS) is a common multisystem disorder with reproductive, cardiometabolic and psychological implications. Genetic factors play a role in the pathogenesis of PCOS. We sought to investigate the cardiometabolic health of first degree relatives (FDR) of women with PCOS.

Design: Systematic review and meta-analysis.

Methods: Medline, Embase, PsycInfo, allEBM (Ovid), clinicaltrials.gov and WHO ICTRP were searched from inception until 1st November 2023. Randomised controlled trials, observational studies, evidence-based guidelines, systematic reviews and health technology assessments reporting on cardiometabolic health of FDRs of women with PCOS compared to participants without a family history of PCOS (controls) were included. Primary outcomes of interest were cardiovascular disease and cardiometabolic risk factors. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were adhered to for the systematic review and meta-analysis.

Results: The search strategy identified 20,639 publications of which 68 publications representing 34 unique studies were included. FDRs of women with PCOS had higher rates of metabolic syndrome (OR: 2.50; 95% CI: 1.40-4.45, I² = 65%; six studies; 2059 participants; p = 0.002), hypertension (OR: 2.05; 95% CI: 1.08-3.92, I² = 0%; three studies; 302 participants; p = 0.03) and diabetes (OR: 2.46; 95% CI: 1.31-4.62, I2 = 9%; five studies; 778 participants; p = 0.005) compared with controls. Additionally, measures of glucose control and lipid profile were worse in FDRs of women with PCOS compared with controls. Most studies were judged as moderate risk of bias. No published data on CVD were identified.

Conclusions: FDRs of women with PCOS are at increased risk of cardiometabolic disorders.

查看原文本刊更多论文

多囊卵巢综合征（PCOS）女性一级亲属的心脏代谢风险

目的：多囊卵巢综合征（PCOS）是一种常见的多系统疾病，具有生殖、心脏代谢和心理方面的影响。遗传因素在多囊卵巢综合征的发病机制中起重要作用。我们试图调查多囊卵巢综合征（PCOS）女性的一级亲属（FDR）的心脏代谢健康。设计：系统回顾和荟萃分析。方法：检索Medline、Embase、PsycInfo、allEBM （Ovid）、clinicaltrials.gov和WHO ICTRP，检索时间为建站至2023年11月1日。随机对照试验、观察性研究、循证指南、系统评价和健康技术评估报告了与无PCOS家族史的参与者（对照组）相比，PCOS女性fdr的心脏代谢健康状况。研究的主要结局是心血管疾病和心血管代谢危险因素。系统评价和荟萃分析遵循系统评价和荟萃分析首选报告项目（PRISMA）指南。结果：检索策略确定了20,639份出版物，其中68份出版物代表34项独特的研究。PCOS女性的fdr有较高的代谢综合征发生率(OR: 2.50；95% ci: 1.40-4.45, i2 = 65%；六项研究;2059名参与者;p = 0.002)，高血压(OR: 2.05；95% ci: 1.08-3.92, i2 = 0%；三个研究;302名参与者;p = 0.03)和糖尿病(OR: 2.46；95% ci: 1.31-4.62, i2 = 9%；五个研究;778名参与者;P = 0.005)。此外，与对照组相比，PCOS女性fdr患者的血糖控制和血脂水平更差。大多数研究被判定为中度偏倚风险。未发现关于心血管疾病的已发表数据。结论：PCOS女性的fdr发生心脏代谢紊乱的风险增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Endocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

3.10%

发文量

192

审稿时长

1 months

期刊介绍： Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.